X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Rating of “Hold” from Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned an average recommendation of “Hold” from the five ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $8.50.

A number of brokerages have recently issued reports on XFOR. Wall Street Zen raised shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings downgraded shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Finally, Guggenheim began coverage on shares of X4 Pharmaceuticals in a report on Monday, March 9th. They issued a “buy” rating and a $12.00 price target on the stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Indivisible Partners purchased a new stake in shares of X4 Pharmaceuticals in the fourth quarter worth about $40,000. Squarepoint Ops LLC purchased a new stake in shares of X4 Pharmaceuticals in the fourth quarter worth about $50,000. Two Sigma Investments LP purchased a new stake in shares of X4 Pharmaceuticals in the third quarter worth about $47,000. Stifel Financial Corp purchased a new stake in shares of X4 Pharmaceuticals in the fourth quarter worth about $82,000. Finally, Virtu Financial LLC purchased a new stake in shares of X4 Pharmaceuticals in the fourth quarter worth about $90,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Price Performance

Shares of NASDAQ:XFOR opened at $4.43 on Monday. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $417.84 million, a PE ratio of -0.98 and a beta of 0.31. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.83. The company has a 50-day moving average price of $4.03 and a two-hundred day moving average price of $3.82.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The firm had revenue of $2.71 million during the quarter, compared to analyst estimates of $3.20 million. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. Equities analysts forecast that X4 Pharmaceuticals will post -0.77 EPS for the current year.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.